Compare Eli Lilly And Co (LLY) vs Progressive Corp (PGR) Price & Performance

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.

Progressive Corporation (PGR) trades at $218.51, up 2.05% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with 12.85% net income margin and 34.94% ROE, supported by consistent revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent earnings beat expectations in Q2 2026 with EPS of $4.85 versus $4.64 expected, though Q1 2026 slightly missed. Analyst consensus price target is $222.23 with 38.1% buy ratings.

PGR presents a favorable risk-reward profile with upside to consensus targets, though near-term overbought RSI conditions warrant caution. The insurance giant's telematics advantage and underwriting discipline provide competitive moat, while intensifying auto insurance competition represents the primary business risk. Current valuation at 10.97 P/E appears reasonable given growth trajectory and profitability metrics.